COVID-19 vaccines for rapid global impact.
作者信息
Hill Adrian V S
机构信息
The Jenner Institute, Oxford University, Oxford, UK.
出版信息
BJU Int. 2021 Feb;127(2):137-139. doi: 10.1111/bju.15339.
Abstract
摘要
相似文献
1
COVID-19 vaccines for rapid global impact.具有快速全球影响力的新冠疫苗。
BJU Int. 2021 Feb;127(2):137-139. doi: 10.1111/bju.15339.
2
Supporting efforts for a global COVID-19 vaccine.支持全球新冠疫苗的相关努力。
Br J Nurs. 2021 Jan 14;30(1):6. doi: 10.12968/bjon.2021.30.1.6.
3
Access to COVID-19 vaccines: looking beyond COVAX.获得新冠疫苗：超越新冠疫苗全球获取机制（COVAX）的视角
Lancet. 2021 Mar 13;397(10278):941. doi: 10.1016/S0140-6736(21)00617-6.
4
Equitable access to COVID-19 vaccination: a distant dream?公平获得新冠疫苗接种：一个遥不可及的梦想？
Eur J Public Health. 2020 Dec 11;30(6):1039-1040. doi: 10.1093/eurpub/ckaa190.
5
COVID-19 Vaccine: Promoting Vaccine Acceptance.新型冠状病毒肺炎疫苗：促进疫苗接种。
Ann Intern Med. 2021 Feb;174(2):252-253. doi: 10.7326/M20-8008. Epub 2020 Dec 21.
6
Covid-19 vaccination-we need more than the 'mum test'.新冠疫苗接种——我们需要的不止是“妈妈测试”。
Drug Ther Bull. 2021 Jan;59(1):2. doi: 10.1136/dtb.2020.000071. Epub 2020 Dec 1.
7
The commitment for fair distribution of COVID-19 vaccine among all countries of the world.在世界各国之间公平分配新冠疫苗的承诺。
Res Nurs Health. 2021 Apr;44(2):266-267. doi: 10.1002/nur.22112. Epub 2021 Feb 1.
8
Vaccinating the world against COVID-19: getting the delivery right is the greatest challenge.为全球接种新冠疫苗：确保疫苗交付顺利是最大的挑战。
BMJ Glob Health. 2021 Mar;6(3). doi: 10.1136/bmjgh-2021-005273.
9
Equitable global access to coronavirus disease 2019 vaccines.2019冠状病毒病疫苗在全球的公平可及性。
BMJ. 2020 Dec 15;371:m4735. doi: 10.1136/bmj.m4735.
10
An update on the global vaccine development for coronavirus.冠状病毒全球疫苗研发的最新情况。
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2053-2055. doi: 10.1016/j.dsx.2020.10.023. Epub 2020 Oct 23.
引用本文的文献
1
A Metasynthesis and Meta-analysis of the Impact and Diagnostic Safety of COVID-19 Symptom Agnostic Rapid Testing in Low- and Middle-Income Countries: Protocol for a Systematic Review.低收入和中等收入国家中新冠病毒症状无关快速检测的影响及诊断安全性的综合分析与荟萃分析：一项系统评价方案
JMIR Res Protoc. 2023 Jan 5;12:e41132. doi: 10.2196/41132.
本文引用的文献
1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
2
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
3
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
4
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.安全性和免疫原性的异源和同源 2 剂量方案的腺病毒血清型 26 和改良痘苗安卡拉载体埃博拉疫苗：一项随机、对照的 1 期研究。
J Infect Dis. 2022 Sep 4;226(4):595-607. doi: 10.1093/infdis/jiaa586.
5
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.SARS-CoV-2 重组刺突蛋白纳米颗粒疫苗的 1/2 期临床试验。
N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.
6
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.ChAdOx1 nCoV-19 疫苗可预防恒河猴的 SARS-CoV-2 肺炎。
Nature. 2020 Oct;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
7
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.重组 5 型腺病毒载体 COVID-19 疫苗在 18 岁及以上健康成年人中的免疫原性和安全性：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20.
8
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.一种中东呼吸综合征冠状病毒病毒载体候选疫苗的安全性和免疫原性：剂量递增、开放性、非随机、非对照、1 期临床试验。
Lancet Infect Dis. 2020 Jul;20(7):816-826. doi: 10.1016/S1473-3099(20)30160-2. Epub 2020 Apr 21.
9
Viral vectors as vaccine platforms: from immunogenicity to impact.病毒载体作为疫苗平台：从免疫原性到影响。
Curr Opin Immunol. 2016 Aug;41:47-54. doi: 10.1016/j.coi.2016.05.014. Epub 2016 Jun 7.
10
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.一种用改良痘苗病毒安卡拉加强免疫的单价黑猩猩腺病毒埃博拉疫苗。
N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.
Zotero 插件